A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects.

Trial Profile

A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2010

At a glance

  • Drugs Moxifloxacin; Telaprevir
  • Indications Bacterial infections; Hepatitis C
  • Focus Pharmacodynamics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 02 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Sep 2009 Actual initiation date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 30 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top